Back to basics for idiosyncratic drug-induced liver injury: Dose and metabolism make the poison

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 6-7, 2010, Pages 348-350

  Ballet, F ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GENERIC DRUG;

ARTICLE; CYTOTOXICITY; DRUG DOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; HUMAN; LIVER CELL DAMAGE; LIVER METABOLISM; PRESCRIPTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK FACTOR; RISK REDUCTION; TOXIC HEPATITIS;

EID: 77955341032     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.04.015     Document Type: Article

References (14)

1. Chalasani N., Fontana R.J., Bonkowski H.L., et al. Causes, clinical features and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
2. Watkins P.B., Seligman P.J., Pears J.S., et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008, 48:1680-1689.
3. Kindmark A., Jawaid A., Harbron C.G., et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008, 8:186-195.
4. Lee W.M., Larrey D., Olsson R., et al. Hepatic findings in long-term clinical trial of ximelagatran. Drug Saf 2005, 28:351-370.
5. Chojkier M Troglitazone and liver injury: in search of answers. Hepatology 2005, 41:237-247.
6. Bannwarth B., Berenbaum F. Lumiracoxib in the management of osteoarthritis and acute pain. Expert Opin Pharmacother 2007, 8:1551-1564.
7. Olson H., Betton G., Robinson D. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Tox Pharmacol 2000, 32:56-67.
8. Muster W., Breidenbach A., Fischer H., et al. Computational toxicology in drug development. Drug Disc Today 2008, 13:303-310.
9. Evans D.C., Baillie T.A. Minimizing the potential for metabolic activation as an integral part of drug design. Cur Opin Drug Disc Dev 2002, 8:44-50.
10. Kenne K., Skanbaerg I., Glinghammar B., et al. Prediction of drug-induced liver injury in human by using in vitro methods: the case of ximelagatran. Toxicol in vitro 2008, 22:730-746.
11. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009, 29:400-411.
12. Lammert C., Einarsson S., Saha C., Niklasson A., Bjornsson E., Chalasani N. Relationship between daily dose of oral medications and idiosyncratic liver-injury: search for signal. Hepatology 2008, 47:2003-2009.
13. Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Cur Opin Drug Discov Dev 2001, 4:55-59.
14. Lammert C., Bjornsson E., Niklasson A., Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse event. Hepatology 2010, 51:615-620.